The 8 most recent market catalysts affecting $NTHI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 55
NeOnc Technologies CEO Amir Heshmatpour Reports Open-Market Share Purchases
This 8-K filing discloses that NeOnc Technologies' CEO, Amir Heshmatpour, made a significant open-market purchase of company shares, adding to his substantial investments throughou…
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 65
NeOnc Technologies Holdings CEO Amir Heshmatpour Purchases 70,000 Additional Shares
NeOnc Technologies Holdings CEO Amir Heshmatpour acquired 70,000 shares of NTHI stock in open market transactions, investing over $230,000. This significant insider purchase, follo…
Oct 27, 2026
Corporate Catalyst
Bullish
Impact 75
NeOnc Technologies Outlines Plans for International Brain Cancer Clinical Trial
NeOnc Technologies Holdings, Inc. (NTHI) has announced a substantial expansion of its clinical development efforts for its proprietary brain cancer drug, NEO100. The company plans …
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Roth Capital Initiates Coverage On NeOnc Technologies Hldgs with Buy Rating, Announces Price Target of $20
Roth Capital analyst Jonathan Aschoff has initiated coverage on NeOnc Technologies Hldgs (NTHI) with a 'Buy' rating and a $20 price target. This event is significant because new an…
Sep 16, 2026
Corporate Catalyst
Neutral
Impact 55
NeOnc Announces Executive Chairman, President And CEO Amir Heshmatpour Purchases Additional 35K Of Company Shares For ~$115,400, At Weighted Average Price Of ~$3.30/Shr
NeOnc Technologies Holdings, Inc. announced that its CEO, Amir Heshmatpour, purchased 35,000 shares of the company's common stock for approximately $115,400. This insider transacti…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 75
NeOnc Technologies Enters $15M Securities Purchase Agreements In At‑The‑Market Offering
NeOnc Technologies has secured approximately $15 million through an at-the-market offering, selling shares and warrants to institutional investors. This capital infusion is crucial…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on NeOnc Technologies Hldgs, Maintains $15 Price Target
BTIG analyst Thomas Shrader has reaffirmed a 'Buy' rating and a $15 price target for NeOnc Technologies Hldgs (NTHI). This action signals that the analyst's previous positive outlo…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 95
NeOnc Technologies Q2 EPS $(0.58) Misses $(0.15) Estimate
NeOnc Technologies (NTHI) announced Q2 earnings per share of $(0.58), which dramatically missed the analyst consensus estimate of $(0.15). This 286.67% miss, coupled with a 93.33% …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.